

Table 6A.B.2.1: Frequency and Survivorship of Soft Tissue Cancers, by Group, United States 2004-2015

Histology [2]	Frequency Count	Percent of Total Frequency	Probability of Survival at Stated Interval [1]			
			24 Month		60 Month	
			Survival Distribution Function (SDF)	SDF 95% Confidence Interval	Survival Distribution Function (SDF)	SDF 95% Confidence Interval
Liposarcoma—all types	11,446	16.60	0.87	0.86-0.87	0.75	0.74-0.76
Leiomyosarcoma—all types	8,858	12.84	0.73	0.72-0.74	0.55	0.54-0.56
Sarcoma, NOS	5,643	8.18	0.54	0.53-0.56	0.43	0.41-0.44
Malignant fibrous histiocytoma	4,965	7.20	0.72	0.71-0.73	0.56	0.54-0.57
Giant cell sarcoma (excluding bone)	4,179	6.05	0.67	0.65-0.68	0.51	0.49-0.53
Synovial cell sarcoma—all types	3,582	5.19	0.81	0.80-0.82	0.64	0.62-0.66
Fibromyxosarcoma	3,297	4.78	0.89	0.88-0.90	0.77	0.76-0.79
Rhabdomyosarcoma—all types	2,963	4.30	0.65	0.63-0.66	0.47	0.45-0.49
Spindle cell sarcoma	2,795	4.05	0.58	0.56-0.60	0.45	0.43-0.47
Malignant peripheral nerve sheath tumor	2,458	3.56	0.63	0.61-0.65	0.50	0.48-0.52
Hemangiosarcoma	2,235	3.24	0.41	0.39-0.43	0.25	0.23-0.27
Dermatofibrosarcoma—all types	2,198	3.19	0.99	0.98-0.99	0.96	0.95-0.97
Chondrosarcoma—all types	1,189	1.72	0.81	0.79-0.83	0.70	0.67-0.73
Undifferentiated sarcoma	1,131	1.64	0.63	0.60-0.66	0.50	0.46-0.53
Fibrosarcoma (excluding infantile FS)	1,069	1.55	0.79	0.76-0.81	0.64	0.61-0.68
Ewing sarcoma	998	1.45	0.73	0.71-0.76	0.61	0.58-0.64
Epithelioid sarcoma	945	1.37	0.68	0.65-0.71	0.55	0.51-0.58
Neuroblastoma—all types	878	1.27	0.90	0.88-0.92	0.82	0.79-0.85
Primitive (and peripheral) neuroectodermal tumor	565	0.82	0.70	0.66-0.74	0.53	0.49-0.58
Squamous cell carcinoma—multiple types	548	0.79	0.56	0.52-0.61	0.42	0.37-0.47
Myxosarcoma	511	0.74	0.82	0.79-0.86	0.70	0.66-0.75
Osteosarcoma—all types	451	0.65	0.61	0.56-0.66	0.44	0.39-0.49
Desmoplastic small round cell tumor	431	0.62	0.55	0.50-0.60	0.18	0.14-0.23
Clear cell sarcoma, NOS (except of kidney M-8964/3)	426	0.62	0.68	0.63-0.72	0.51	0.46-0.56
Solitary fibrous tumor—malignant	394	0.57	0.79	0.75-0.84	0.64	0.58-0.70
TOTALS	64,155	92.99				

[1] Example: The probability of survival at 24 months from diagnosis for Liposarcma-all types is 87% (confidential interval 86% to 87%) and at 60 months it is 75% (confidential interval 74% to 76%).

[2] Only groups in which at least one subtype contained at least 200 cases are illustrated in this table. See data by individual subgroup diagnosis for most accurate data regarding survival statistics.

Source: The National Cancer Data Base (NCDB) of the American College of Surgeons (ACS), 2004-2015.